Abstract Search

ea0084op-07-34 | Oral Session 7: Thyroid Cancer Basic | ETA2022

CDK4 phosphorylation status and rational use of CDK4/6 inhibitors in advanced thyroid cancers

Pita Jaime M , Coulonval Katia , Costante Giuseppe , Myriam Decaussin , Emmanuelle Leteurtre , Cavaco Branca , A Copland John , Durante Cosimo , Maenhaut Carine , Dumont Jacques , Roger Pierre , Raspe Eric

Introduction and objectives: The cyclin-dependent kinases CDK4 and CDK6 are key regulators of the cell cycle entry, by phosphorylating the onco-suppressor retinoblastoma protein (pRb). CDK4/6 inhibitors (CDK4i) are already established as standard first-line treatment against advanced Estrogen Receptor-positive breast tumors, and have emerged as novel drugs to treat various pRb-proficient chemotherapy-resistant cancers. Presence of activating T172-phosphorylation of CDK4 in bre...

1 shares

ea0070aep860 | Thyroid | ECE2020

The natural history of benign thyroid nodules: 10 years follow-up

Ramundo Valeria , Grani Giorgio , Bruno Rocco , Costante Giuseppe , Meringolo Domenico , Puxeddu Efisio , Torlontano Massimo , Tumino Salvatore , Lucisano Giuseppe , Nicolucci Antonio , Filetti Sebastiano , Durante Cosimo

Background and Aim: The incidental detection of asymptomatic thyroid nodules (TNs) has increased over time. Over 90% of newly diagnosed TNs are either cytologically or sonographically benign. This study aimed to determine the frequency and magnitude of changes in TNs size over time.Methods: We performed a prospective, multicenter, observational study involving consecutive euthyroid patients with 1–4 asymptomatic, sonographically or cytological...

0 shares

Endocrine Abstracts

CDK4 phosphorylation status and rational use of CDK4/6 inhibitors in advanced thyroid cancers

The natural history of benign thyroid nodules: 10 years follow-up

BiosciAbstracts